NVST

Envista Holdings Corp
7 filings tracked
healthcaremedical devicesMID ($2B-10B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Envista Holdings is demonstrating a powerful inflection in profitability, characterized by a dramatic surge in net income and expanding operating margins. For the first quarter of 2026, the company reported a 115% increase in net income, supported by a 9.5% growth in core sales.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the headline earnings growth, a closer look at Envista's cash flow reveals a concerning disconnect. The company reported a net cash outflow from operating activities of $3.3 million for the quarter, contrasting sharply with the reported net income surge.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every NVST filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing presents a dichotomy between accounting profitability and cash reality. On one hand, Envista is successfully growing its top line and expanding its operating margins, proving that its dental portfolio remains resilient and capable of absorbing fixed costs. The shift toward higher-margin segments and the strategic move into advanced aligner technology via the Versah acquisition provide a clear path for long-term growth. The company's ability to maintain gross margins at 55.3% despite tariff headwinds suggests a disciplined approach to supply chain and pricing management. However, the disconnect between net income and operating cash flow, paired with a heavy debt profile, introduces a layer of financial risk. Investors must weigh the impressive earnings acceleration against the reality of negative operating cash flow and the reliance on tax-driven bottom-line boosts. The overall impact of the filing is a company in a high-growth transition phase, where the success of its strategic investments and the management of its leverage will determine if it can transform this accounting momentum into sustainable, cash-backed compounding.

Selected Quarter

Core Takeaway

The company is achieving strong operational leverage and sales growth, but the quality of earnings is questioned by negative operating cash flow and high leverage.

Investor Lens

The trade-off is between impressive GAAP earnings growth and deteriorating cash flow quality.

Watch Next

The ability to return to positive operating cash flow in Q2 and the integration success of the Versah acquisition.

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.67Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 6

Net income surged 115% year-over-year to $38.7 million.

earnings beat
90%
bullishMay 6

Operating profit increased 60% to $62.5 million, with Equipment & Consumables margins hitting 18.9%.

margin expansion
70%
bullishMay 6

New $300 million stock repurchase program authorized through 2029.

buyback
60%
bullishMay 6

Acquired Versah LLC for approximately $54.7 million to expand orthodontic technology.

acquisition
50%
bullishMay 6

Net income surged 115% year-over-year to $38.7 million.

earnings beat
90%
bullishMay 6

Operating profit increased 60% to $62.5 million, with Equipment & Consumables margins hitting 18.9%.

margin expansion
70%
bullishMay 6

New $300 million stock repurchase program authorized through 2029.

buyback
60%
bullishMay 6

Acquired Versah LLC for approximately $54.7 million to expand orthodontic technology.

acquisition
50%
bullishMay 6

Net income surged 115% year-over-year to $38.7 million.

earnings beat
90%
bullishMay 6

Operating profit increased 60% to $62.5 million, with Equipment & Consumables margins hitting 18.9%.

margin expansion
70%
bullishMay 6

New $300 million stock repurchase program authorized through 2029.

buyback
60%
bullishMay 6

Acquired Versah LLC for approximately $54.7 million to expand orthodontic technology.

acquisition
50%
bullishMay 6

Net income surged 115% year-over-year to $38.7 million.

earnings beat
90%
bullishMay 6

Operating profit increased 60% to $62.5 million, with Equipment & Consumables margins hitting 18.9%.

margin expansion
70%
bullishMay 6

New $300 million stock repurchase program authorized through 2029.

buyback
60%
bullishMay 6

Acquired Versah LLC for approximately $54.7 million to expand orthodontic technology.

acquisition
50%
bullishMay 6

Net income surged 115% year-over-year to $38.7 million.

earnings beat
90%
bullishMay 6

Operating profit increased 60% to $62.5 million, with Equipment & Consumables margins hitting 18.9%.

margin expansion
70%
bullishMay 6

New $300 million stock repurchase program authorized through 2029.

buyback
60%
bullishMay 6

Acquired Versah LLC for approximately $54.7 million to expand orthodontic technology.

acquisition
50%
bullishMay 6

Net income surged 115% year-over-year to $38.7 million.

earnings beat
90%
bullishMay 6

Operating profit increased 60% to $62.5 million, with Equipment & Consumables margins hitting 18.9%.

margin expansion
70%
bullishMay 6

New $300 million stock repurchase program authorized through 2029.

buyback
60%
bullishMay 6

Acquired Versah LLC for approximately $54.7 million to expand orthodontic technology.

acquisition
50%
bullishMay 6

Net income surged 115% year-over-year to $38.7 million.

earnings beat
90%
bullishMay 6

Operating profit increased 60% to $62.5 million, with Equipment & Consumables margins hitting 18.9%.

margin expansion
70%
bullishMay 6

New $300 million stock repurchase program authorized through 2029.

buyback
60%
bullishMay 6

Acquired Versah LLC for approximately $54.7 million to expand orthodontic technology.

acquisition
50%

Filing History

10-QMay 6, 2026
Expand Sequence

The Q1 2026 filing presents a dichotomy between accounting profitability and cash reality. On one hand, Envista is successfully growing its top line and expanding its operating margins, proving that its dental portfolio remains resilient and capable of absorbing fixed costs. The shift toward higher-margin segments and the strategic move into advanced aligner technology via the Versah acquisition provide a clear path for long-term growth. The company's ability to maintain gross margins at 55.3% despite tariff headwinds suggests a disciplined approach to supply chain and pricing management. However, the disconnect between net income and operating cash flow, paired with a heavy debt profile, introduces a layer of financial risk. Investors must weigh the impressive earnings acceleration against the reality of negative operating cash flow and the reliance on tax-driven bottom-line boosts. The overall impact of the filing is a company in a high-growth transition phase, where the success of its strategic investments and the management of its leverage will determine if it can transform this accounting momentum into sustainable, cash-backed compounding.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.